Vancouver, British Columbia - November 22, 2016 - NeutriSci International Inc. (the "Company" or "NeutriSci") (TSX-V: NU, Frankfurt-1N9) and Lexaria Bioscience Corp. ("Lexaria") (LXX.CN) are pleased to announce the signing of a Memorandum of Understanding forming a 50/50 Joint Venture (the "JV") to develop and produce a line of healthy edible cannabinoid products using Lexaria's patented technology and NeutriSci's proprietary pterostilbene tablet formula and to distribute the products through NeutriSci's international distribution network.

This JV will test and develop cannabinoid formulations based on NeutriSci's proprietary sublingual pterostilbene zero-sugar tablet formula and form factor; combining Lexaria's patented technology which improves the bioavailability and taste of orally ingested cannabinoids. Under the JV, the companies will first develop its edible product using cannabidiol (CBD) derived from full spectrum hemp oil, which is legal throughout the United States, followed by further development using other cannabinoid products such as tetrahydrocannabinol (THC). The JV will ultimately commercialize these potentially unique and proprietary edible products through distribution programs with existing strategic partners.